EU authorises Celltrion’s adalimumab biosimilar Yuflyma
Yuflyma is approved across 13 indications for the treatment of multiple chronic inflammatory diseases
Read More
Tag: Yuflyma
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
